These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

783 related articles for article (PubMed ID: 26424759)

  • 1. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
    Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
    Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status.
    Shin SJ; Jeon YK; Kim PJ; Cho YM; Koh J; Chung DH; Go H
    Ann Surg Oncol; 2016 Feb; 23(2):694-702. PubMed ID: 26464193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sarcomatoid features, necrosis, and grade are prognostic factors in metastatic clear cell renal cell carcinoma with vascular endothelial growth factor-targeted therapy.
    Park JY; Lee JL; Baek S; Eo SH; Go H; Ro JY; Cho YM
    Hum Pathol; 2014 Jul; 45(7):1437-44. PubMed ID: 24784922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma.
    Nadal R; Amin A; Geynisman DM; Voss MH; Weinstock M; Doyle J; Zhang Z; Viudez A; Plimack ER; McDermott DF; Motzer R; Rini B; Hammers HJ
    Ann Oncol; 2016 Jul; 27(7):1304-11. PubMed ID: 27059553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas.
    Kim S; Kim MY; Koh J; Go H; Lee DS; Jeon YK; Chung DH
    Eur J Cancer; 2015 Nov; 51(17):2698-707. PubMed ID: 26329973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma.
    Albiges L; Fay AP; Xie W; Krajewski K; McDermott DF; Heng DY; Dariane C; DeVelasco G; Lester R; Escudier B; Choueiri TK
    Eur J Cancer; 2015 Nov; 51(17):2580-6. PubMed ID: 26346135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma.
    Seidel C; Busch J; Weikert S; Steffens S; Fenner M; Ganser A; Grünwald V
    Eur J Cancer; 2012 May; 48(7):1023-30. PubMed ID: 22436979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
    Darb-Esfahani S; Kunze CA; Kulbe H; Sehouli J; Wienert S; Lindner J; Budczies J; Bockmayr M; Dietel M; Denkert C; Braicu I; Jöhrens K
    Oncotarget; 2016 Jan; 7(2):1486-99. PubMed ID: 26625204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
    Kim MY; Koh J; Kim S; Go H; Jeon YK; Chung DH
    Lung Cancer; 2015 Apr; 88(1):24-33. PubMed ID: 25662388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor.
    Sacré A; Barthélémy P; Korenbaum C; Burgy M; Wolter P; Dumez H; Lerut E; Loyson T; Joniau S; Oyen R; Debruyne PR; Schöffski P; Beuselinck B
    Acta Oncol; 2016; 55(3):329-40. PubMed ID: 26494607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs.
    Tang Y; Fang W; Zhang Y; Hong S; Kang S; Yan Y; Chen N; Zhan J; He X; Qin T; Li G; Tang W; Peng P; Zhang L
    Oncotarget; 2015 Jun; 6(16):14209-19. PubMed ID: 25895031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic tissue biomarker exploration for patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Park I; Cho YM; Lee JL; Ahn JH; Lee DH
    Tumour Biol; 2016 Apr; 37(4):4919-27. PubMed ID: 26526582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression pattern of immune checkpoint-associated molecules in radical nephrectomy specimens as a prognosticator in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
    Hara T; Miyake H; Fujisawa M
    Urol Oncol; 2017 Jun; 35(6):363-369. PubMed ID: 28169111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic significance of PD-L1 in bladder cancer.
    Huang Y; Zhang SD; McCrudden C; Chan KW; Lin Y; Kwok HF
    Oncol Rep; 2015 Jun; 33(6):3075-84. PubMed ID: 25963805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.
    Calles A; Liao X; Sholl LM; Rodig SJ; Freeman GJ; Butaney M; Lydon C; Dahlberg SE; Hodi FS; Oxnard GR; Jackman DM; Jänne PA
    J Thorac Oncol; 2015 Dec; 10(12):1726-35. PubMed ID: 26473645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No Significant Correlation of Clinical Outcomes Between First- and Second-line Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma.
    Miyazaki A; Miyake H; Harada K; Fujisawa M
    Anticancer Res; 2015 May; 35(5):3067-73. PubMed ID: 25964597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC).
    Abbas M; Steffens S; Bellut M; Eggers H; Großhennig A; Becker JU; Wegener G; Schrader AJ; Grünwald V; Ivanyi P
    Med Oncol; 2016 Jul; 33(7):80. PubMed ID: 27317388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial.
    Choueiri TK; Figueroa DJ; Fay AP; Signoretti S; Liu Y; Gagnon R; Deen K; Carpenter C; Benson P; Ho TH; Pandite L; de Souza P; Powles T; Motzer RJ
    Clin Cancer Res; 2015 Mar; 21(5):1071-7. PubMed ID: 25538263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do programmed death 1 (PD-1) and its ligand (PD-L1) play a role in patients with non-clear cell renal cell carcinoma?
    Abbas M; Steffens S; Bellut M; Becker JU; Großhennig A; Eggers H; Wegener G; Kuczyk MA; Kreipe HH; Grünwald V; Schrader AJ; Ivanyi P
    Med Oncol; 2016 Jun; 33(6):59. PubMed ID: 27165272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of immunohistochemical staining with ezrin-carbonic anhydrase IX and neuropilin-2 on prognosis in patients with metastatic renal cell cancer receiving tyrosine kinase inhibitors.
    Cetin B; Gonul II; Buyukberber S; Afsar B; Gumusay O; Algın E; Turan N; Ozet A; Benekli M; Coskun U
    Tumour Biol; 2015 Nov; 36(11):8471-8. PubMed ID: 26026587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.